A PHASE 2 STUDY OF ALKS 4230 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED OR RECURRENT HEAD AND NECK SQUAMOUS CELL CANCER CURRENTLY ON TREATENT WITH ANTI-PD-(L)1 WITHOUT HAVING ACHIEVED A COMPLETE REMISSION

Brief description of study

The purpose of this study is to see how well ALKS 4230 (IL-2 and IL-2 receptor (R; IL-2R)) works together with the drug Prembrolizumab to treat advanced or recurrent head and neck cancer in people who have not responded to other Immune-targeted treatment. Additionally, to learn how long any responses to the combination of ALKS 4230 and Pembrolizumab last. Also, if there are side effects caused by ALKS 4230 given together with pembrolizumab in this setting and how well the body responds to it.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.